Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
Status:
Completed
Trial end date:
2018-01-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the effect of reslizumab (110 mg)
administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and
adolescents with asthma and elevated blood eosinophils who are inadequately controlled on
standard-of-care asthma therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.